196 related articles for article (PubMed ID: 18958767)
1. Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome.
Karakurt F; Gumus II; Bavbek N; Kargili A; Koca C; Selcoki Y; Ozbek M; Kosar A; Akcay A
Gynecol Endocrinol; 2008 Sep; 24(9):491-7. PubMed ID: 18958767
[TBL] [Abstract][Full Text] [Related]
2. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
Oral B; Mermi B; Dilek M; Alanoğlu G; Sütçü R
Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106
[TBL] [Abstract][Full Text] [Related]
3. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome.
Erdoğan M; Karadeniz M; Alper GE; Tamsel S; Uluer H; Cağlayan O; Saygili F; Yilmaz C
Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):143-7. PubMed ID: 18350479
[TBL] [Abstract][Full Text] [Related]
4. The effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome.
Gul OB; Somunkiran A; Yucel O; Demirci F; Ozdemir I
Arch Gynecol Obstet; 2008 Jan; 277(1):25-30. PubMed ID: 17618446
[TBL] [Abstract][Full Text] [Related]
5. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
Luque-Ramírez M; Alvarez-Blasco F; Uriol Rivera MG; Escobar-Morreale HF
Hum Reprod; 2008 Jul; 23(7):1594-601. PubMed ID: 18375410
[TBL] [Abstract][Full Text] [Related]
6. Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate.
Markantes G; Saltamavros AD; Vervita V; Armeni AK; Karela A; Adonakis G; Decavalas G; Georgopoulos NA
Gynecol Endocrinol; 2011 Dec; 27(12):971-7. PubMed ID: 21501001
[TBL] [Abstract][Full Text] [Related]
7. [The effects of oxidative stress to PCOS].
Zhang D; Luo WY; Liao H; Wang CF; Sun Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 May; 39(3):421-3. PubMed ID: 18575330
[TBL] [Abstract][Full Text] [Related]
8. How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?
Kabil Kucur S; Gozukara I; Aksoy A; Uludag EU; Keskin H; Kamalak Z; Carlioglu A
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):862-5. PubMed ID: 25402193
[TBL] [Abstract][Full Text] [Related]
9. Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women: the effect of cyproterone acetate-ethinyl estradiol treatment.
Luboshitzky R; Herer P; Shen-Orr Z
Exp Clin Endocrinol Diabetes; 2004 Feb; 112(2):102-7. PubMed ID: 15031776
[TBL] [Abstract][Full Text] [Related]
10. Weight change and androgen levels during contraceptive treatment of women affected by polycystic ovary.
Vrbikova J; Dvorakova K; Hill M; Starka L
Endocr Regul; 2006 Dec; 40(4):119-23. PubMed ID: 17201585
[TBL] [Abstract][Full Text] [Related]
11. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state.
Yildiz BO; Haznedaroğlu IC; Kirazli S; Bayraktar M
J Clin Endocrinol Metab; 2002 Aug; 87(8):3871-5. PubMed ID: 12161525
[TBL] [Abstract][Full Text] [Related]
12. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases.
Saibeni S; Bottasso B; Spina L; Bajetta M; Danese S; Gasbarrini A; de Franchis R; Vecchi M
Am J Gastroenterol; 2004 Oct; 99(10):1966-70. PubMed ID: 15447757
[TBL] [Abstract][Full Text] [Related]
13. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking.
Luque-Ramírez M; Mendieta-Azcona C; del Rey Sánchez JM; Matíes M; Escobar-Morreale HF
Eur J Endocrinol; 2009 Mar; 160(3):469-80. PubMed ID: 19139031
[TBL] [Abstract][Full Text] [Related]
14. Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.
Güldaş M; Altinkaya SÖ; Nergiz S; Demircan-Sezer S; Yüksel H
Gynecol Endocrinol; 2015 Jul; 31(7):536-9. PubMed ID: 26220768
[TBL] [Abstract][Full Text] [Related]
15. Effect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome.
Karakurt F; Carlioglu A; Kaygusuz I; Gumus II; Uz B; Akdeniz D
Arch Gynecol Obstet; 2014 Jan; 289(1):135-40. PubMed ID: 23880889
[TBL] [Abstract][Full Text] [Related]
16. Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
Donmez A; Aksu K; Celik HA; Keser G; Cagirgan S; Omay SB; Inal V; Aydin HH; Tombuloglu M; Doganavsargil E
Thromb Res; 2005; 115(4):287-92. PubMed ID: 15668188
[TBL] [Abstract][Full Text] [Related]
17. Plasma ghrelin concentrations in patients with polycystic ovary syndrome before and after 6months therapy: correlation with androgen levels.
Kos-Kudła B; Małecka-Mikosz O; Foltyn W; Ostrowska Z; Kudła M; Mazur B
Neuro Endocrinol Lett; 2006 Dec; 27(6):763-7. PubMed ID: 17187005
[TBL] [Abstract][Full Text] [Related]
18. Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity.
Guven GS; Kiliçaslan A; Oz SG; Haznedaroglu IC; Kirazli S; Aslan D; Sözen T
Clin Appl Thromb Hemost; 2006 Jul; 12(3):364-8. PubMed ID: 16959692
[TBL] [Abstract][Full Text] [Related]
19. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
Małyszko J; Małyszko JS; Hryszko T; Myśliwiec M
Thromb Haemost; 2004 Mar; 91(3):480-6. PubMed ID: 14983223
[TBL] [Abstract][Full Text] [Related]
20. Serum high-sensitivity C-reactive protein and homocysteine changes during hormonal therapy in women with polycystic ovary syndrome: a prospective, matched study.
Makedos A; Goulis DG; Papanikolaou A; Panidis D
Angiology; 2010 Aug; 61(6):595-601. PubMed ID: 20395229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
